



## King's Research Portal

DOI:

[10.1016/j.euroneuro.2018.07.101](https://doi.org/10.1016/j.euroneuro.2018.07.101)

*Document Version*

Other version

[Link to publication record in King's Research Portal](#)

*Citation for published version (APA):*

The IMAGEN Consortium, Macare, C., Ducci, F., Zhang, Y., Ruggeri, B., Jia, T., Kaakinen, M., Kalsi, G., Charoen, P., Casoni, F., Peters, J., Bromberg, U., Hill, M., Buxton, J., Blakemore, A., Veijola, J., Büchel, C., Banaschewski, T., Bokde, A. L. W., ... Schumann, G. (2018). A neurobiological pathway to smoking in adolescence: TTC12-ANKK1-DRD2 variants and reward response. *European Neuropsychopharmacology*, 28(10), 1103-1114. <https://doi.org/10.1016/j.euroneuro.2018.07.101>

### **Citing this paper**

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

### **General rights**

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

### **Take down policy**

If you believe that this document breaches copyright please contact [librarypure@kcl.ac.uk](mailto:librarypure@kcl.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.

## **Conflict of Interest**

Dr. Banaschewski has served as an advisor or consultant to Bristol-Myers Squibb, Desitin Arzneimittel, Eli Lilly, Medice, Novartis, Pfizer, Shire, UCB, and Vifor Pharma; he has received conference attendance support, conference support, or speaking fees from Eli Lilly, Janssen McNeil, Medice, Novartis, Shire, and UCB; and he is involved in clinical trials conducted by Eli Lilly, Novartis, and Shire; the present work is unrelated to these relationships. Dr. Gallinat has received research funding from the German Federal Ministry of Education and Research, AstraZeneca, Eli Lilly, Janssen-Cilag, and Bristol-Myers Squibb; he has received speaking fees from AstraZeneca, Janssen-Cilag, and Bristol-Myers Squibb; the present work is unrelated to these relationships. The other authors report no financial interests or potential conflicts of interest.